Considerations for policymakers for improving health care through telegenetics: A points to consider statement of the American College of Medical Genetics and Genomics (ACMG).

Competing Interests: Conflict of Interest H.E.W. serves as a director in a clinical laboratory that performs a breadth of genetic and genomic analyses on a fee for service basis and is an employee of Tempus Labs, Inc and has equity ownership in the form of incentive stock options and restricted stock units. L.A.’s contributions to this document were accomplished in her personal capacity. The views expressed do not necessarily reflect the official views of, nor an endorsement by, the State of Hawai’i Department of Health, the Health Resources & Services Administration, the Department of Health and Human Services, or the United States Government. M.B.D. is employed by eviCore, a testing utilization company. D.F. is a consultant to CareSource, a managed care Medicaid payer. D.V. is a consultant for AstraZeneca, Sanofi, and SpringWorks, as well as the principal investigator for Takeda, Ultragenyx, Levo Therapeutics, and Soleno Therapeutics clinical trials. All other authors declare no conflicts of interest.